Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Penumbra Inc

Start price
Target price
Perf. (%)
€258.00
05.04.23
-
05.04.24
-10.08%
31.01.24

buy
Ensign Group Inc.

Start price
Target price
Perf. (%)
€86.00
04.04.23
-
04.04.24
24.42%
31.01.24

buy
Alphatec Holdings Inc

Start price
Target price
Perf. (%)
€14.88
08.03.23
-
08.03.24
0.17%
31.01.24

buy
Gerresheimer AG

Start price
Target price
Perf. (%)
€83.95
28.02.23
-
28.02.24
13.04%
31.01.24

Cytosorbents Corp.

Start price
Target price
Perf. (%)
€1.83
17.09.23
-
17.09.24
-52.14%
19.01.24

Probably not worthwhile Investment
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.06
26.12.23
-
26.12.24
-8.96%
11.01.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Masimo Corp.

Start price
Target price
Perf. (%)
€178.60
19.04.23
€177.50
19.04.24
-38.97%
27.12.23

buy
Sernova Corp.

Start price
Target price
Perf. (%)
€0.53
30.12.22
€5.00
30.12.25
-10.84%
15.12.23

Could be very worthwhile Investment >20% year
buy
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€33.12
11.10.23
-
11.10.24
14.79%
12.12.23

Known brand
Could be worthwhile Investment >10% per year
Tabula Rasa HealthCare Inc

Start price
Target price
Perf. (%)
€9.35
08.08.23
-
08.08.24
5.88%
11.12.23

Probably not worthwhile Investment
Bovie Medical Corp

Start price
Target price
Perf. (%)
€2.34
16.10.23
-
16.10.24
-15.38%
11.12.23

Risky Investment
Community Health Systems Inc.

Start price
Target price
Perf. (%)
€2.00
30.10.23
-
30.10.24
15.00%
11.12.23

Probably not worthwhile Investment
scPharmaceuticals

Start price
Target price
Perf. (%)
€4.66
13.11.23
-
13.11.24
12.66%
11.12.23

Probably not worthwhile Investment
buy
M1 Kliniken AG

Start price
Target price
Perf. (%)
€6.04
09.12.22
-
09.12.23
68.87%
10.12.23

buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.44
02.12.23
€2.00
02.12.24
-1.29%
05.12.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
Gerresheimer AG

Start price
Target price
Perf. (%)
€72.50
02.12.22
-
02.12.23
22.69%
03.12.23

buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.36
29.11.23
€2.00
29.11.24
3.49%
02.12.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.23
23.11.23
€2.00
23.11.24
5.92%
29.11.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.11
27.09.23
€4.00
27.09.24
5.76%
23.11.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Sartorius AG VZO

Start price
Target price
Perf. (%)
€396.90
15.11.22
-
15.11.23
-30.86%
16.11.23

buy
Crossject S.A.

Start price
Target price
Perf. (%)
€4.04
12.11.22
€4.50
12.11.23
5.82%
13.11.23

Could be worthwhile Investment >10% per year
buy
ShockWave Medical Inc

Start price
Target price
Perf. (%)
€285.40
07.09.22
€400.00
31.12.25
-47.00%
12.11.23

Could be very worthwhile Investment >20% year
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.95
11.11.23
-
11.11.24
-
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.81
05.11.23
-
05.11.24
15.43%
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.01
03.09.23
-
03.09.24
-19.80%
05.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies